Search research articles
Contact Us
Filters
Showing results (151-160 of 302) with videos related to
Page
of 31
Sort By:
British Journal of Haematology
|
April 10, 2015
Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia
Katharine H Xing, Amrit Kahlon, Brian F Skinnider, et al.
Blood
|
April 4, 2008
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
Kerry J Savage, Nancy Lee Harris, Julie M Vose, et al.
International Journal of Cancer
|
July 21, 2007
A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non-Hodgkin lymphoma
Payal Sipahimalani, John J Spinelli, Amy C MacArthur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2012
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study
Barbara Pro, Ranjana Advani, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 7, 2016
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP
Norbert Schmitz, Samira Zeynalova, Maike Nickelsen, et al.
Leukemia & Lymphoma
|
December 29, 2023
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis
Jowon Laura Kim, Alina S Gerrie, Kerry Joane Savage, et al.
Haematologica
|
February 4, 2017
Genetic polymorphism at <i>BCL2</i> as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma
Morteza Bashash, Joseph M Connors, Randy D Gascoyne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2012
International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era
Alden A Moccia, Jane Donaldson, Mukesh Chhanabhai, et al.
Blood
|
July 15, 2009
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
Nathalie A Johnson, Kerry J Savage, Olga Ludkovski, et al.
British Journal of Haematology
|
October 22, 2016
Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience
Greg Hapgood, Tom Pickles, Laurie H Sehn, et al.
Page
of 31
Search research articles
Search
Showing results (151-160 of 302) with videos related to
Sort By:
Page
of 31
British Journal of Haematology
|
April 10, 2015
Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia
Katharine H Xing, Amrit Kahlon, Brian F Skinnider, et al.
Blood
|
April 4, 2008
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
Kerry J Savage, Nancy Lee Harris, Julie M Vose, et al.
International Journal of Cancer
|
July 21, 2007
A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non-Hodgkin lymphoma
Payal Sipahimalani, John J Spinelli, Amy C MacArthur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2012
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study
Barbara Pro, Ranjana Advani, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 7, 2016
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP
Norbert Schmitz, Samira Zeynalova, Maike Nickelsen, et al.
Leukemia & Lymphoma
|
December 29, 2023
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis
Jowon Laura Kim, Alina S Gerrie, Kerry Joane Savage, et al.
Haematologica
|
February 4, 2017
Genetic polymorphism at <i>BCL2</i> as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma
Morteza Bashash, Joseph M Connors, Randy D Gascoyne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2012
International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era
Alden A Moccia, Jane Donaldson, Mukesh Chhanabhai, et al.
Blood
|
July 15, 2009
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
Nathalie A Johnson, Kerry J Savage, Olga Ludkovski, et al.
British Journal of Haematology
|
October 22, 2016
Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience
Greg Hapgood, Tom Pickles, Laurie H Sehn, et al.
Page
of 31